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ABSTRACT 
 
Hendra virus is a lethal zoonotic agent which causes severe respiratory diseases in 
horses and subsequently to humans. The virus is mainly found in flying foxes. The 
high mortality rate of HeV disease in humans (57%) and the increasing outbreaks of 
HeV infection in horses poses a threat to human health. HeV is observed to be 
transmitted to horses from flying foxes and humans may become infected with HeV 
when they come in direct or close contact with the infected horses. With the help of 
current diagnostic tests, the detection of the virus can only be done only after the 
clinical signs and symptoms appear among the host. By studying the host immune 
response towards the infection, the disease can be detected as early as possible. This 
implies detecting the infection well before the signs and symptoms appear. MicroRNA 
analysis has evolved as a potential technique to diagnose the disease as early as 
possible. Many different diseases, including the viral infections, can be diagnosed with 
the help of miRNA expression profiles. Recent study has shown that microRNA 
profiling technique can be considered as a useful tool to diagnose HeV infection in 
earlier stages of infection. MicroRNAs have been evolved as a promising biomarker 
in recent years in differentiating infectious diseases from a healthy control. The 
sensitivity, specificity, robustness and non-invasive nature of miRNA detection makes 
miRNA as an ideal choice for disease biomarker. Although the circulating expression 
profile of a particular microRNA ratio, miR-20a/1842, shows differences between 
healthy and infected horses in some instances, it was not statistically significant, 
suggesting that more extensive research needs to be performed to identify other 
microRNA biomarkers, which when measured in conjunction with miR-20a/1842, 
could progress microRNA as potential biomarkers for early detection of HeV disease. 
This response was not observed in horses vaccinated against HeV, or infected with 
West Nile virus, suggesting some level of specificity. The results from this study show 
that the profiling of host miRNA in a viral infection shows promise as a new approach 
in diagnosing infectious diseases in near future. 
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CHAPTER I: INTRODUCTION 
 
1. HENDRA VIRUS 
 
1.1 PROPERTIES 
Hendra Virus (HeV) is a negative strand RNA virus which belongs to the genus 
Henipavirus and family Paramyxoviridae (Wang et al. 1998; Wang et al. 2000). It is 
a lethal zoonotic agent which causes severe respiratory diseases in horses and 
subsequently to humans (Westbury 2000). The virus size ranges from 40 nm to 600 
nm in diameter (Hyatt et al. 2001). The HeV genome is 18,234 nucleotides in length 
encoding the genes nucleocapsid, phosphoprotein, matrix protein, fusion glycoprotein, 
attachment glycoprotein and large polymerase in the direction of 3’ to 5’. An amino-
terminal domain of nucleocapsid interacts with viral genome whereas the carboxyl-
terminal interacts with the phosphoprotein. The virions are assembled at the cell 
membrane with the help of matrix protein (Mahalingam et al. 2012; Mire, Satterfield 
& Geisbert 2016). Fusion glycoprotein helps in fusion of virus and membrane of the 
host cell whereas the attachment glycoprotein helps in binding of the receptor molecule 
ephrin B2 (Wang et al. 2001). The large polymerase is involved in initiation, 
elongation and termination of mRNA transcription and replication of genome 
(Mahalingam et al. 2012). 
 
1.2 EPIDEMIOLOGY 
HeV is mainly found in flying foxes (Pteropus spp) i.e they are the natural hosts of the 
virus (Halpin et al. 2000; Mahalingam et al. 2012; Young et al. 1996). The cases of 
HeV have only been observed in Australia till date. Mainly, four species of flying 
foxes are found in mainland Australia which are: P. alecto (black flying fox), P. 
conspicillatus (spectacled flying fox), P. scapulatus (little red flying fox) and P. 
poliocephalus (grey headed flying fox). Though many studies have shown that 
neutralising antibodies to HeV have been detected in all these species (Halpin et al. 
2000; Hess et al. 2011; Young et al. 1996), they are not equally efficient hosts of the 
virus. Among these four species, P. alecto and P. conspicillatus are the two species 
which have been identified as major primary reservoirs of the virus (Edson et al. 2015; 
Field et al. 2015; Field 2016; Goldspink et al. 2015). No clinical signs and symptoms 
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are seen in flying foxes whether they are wild type or experimentally infected ones 
(Goldspink et al. 2015; Williamson et al. 1998; Williamson et al. 2000). 
 
1.2.1 DISTRIBUTION OF HENDRA VIRUS 
Although HeV infection has mainly been recorded in Australia, there have been 
serological evidences of the infection in P. admiralitatum, P. capistratus, P. 
hypomelanus and P. neohybernicus from Papua New Guinea (Breed et al. 2013; Halpin 
et al. 1999). Similarly, bats from Asia, China and Africa have been infected with 
related henipaviruses (Hayman et al. 2008; Li et al. 2008; Peel et al. 2012). Based on 
the above surveillance, one cannot deny the fact that the infection might spread to other 
locations outside Australia, as the neutralising antibodies against HeV have been 
observed in other bat species. HeV and Australian bat lyssavirus (in Australia) and 
Nipah virus (in Malaysia and Bangladesh) are the highly lethal viral diseases that have 
a high mortality rate (Hsu et al. 2004; Yob et al. 2001). 
 
1.2.2 HENDRA VIRUS IN AUSTRALIA  
HeV was discovered when an outbreak of severe respiratory disease occurred at a 
horse stable in Hendra (suburb of Brisbane), Queensland Australia in 1994 (Field et 
al. 2007). This initial outbreak resulted in the death of 14 horses along with the death 
of one person (Murray et al. 1995). Since 1994 the outbreaks of HeV has counted to 
83 confirmed cases, all of them occurring in Australia. 23 of those outbreaks has 
occurred in a single year of 2011. Out of 83 outbreaks of HeV infection among horses, 
41 had occurred in between 2011 to 2013 (Business Queensland 2018). Till date 7 
human beings have been infected with HeV infection, out of which 4 people had died. 
The casualty was largely due to the direct or close contact of the individuals with the 
horses infected with HeV but the horses were not showing any clinical signs and 
symptoms at that particular time (Field et al. 2010; Mahalingam et al. 2012; Playford 
et al. 2010). The high mortality rate of HeV disease in humans (57%), the increasing 
outbreaks of HeV infection in horses poses a threat to human health. The latest case of 
HeV infection in horse was recorded in September 2018 in Tweed Heads of New South 
Wales (Business Queensland 2018). The outbreak of HeV infection occurs in those 
areas where the prevalence of P. alecto is high. Recent studies have suggested that the 
outbreak is in peak during winter seasons (Field et al. 2015; Martin et al. 2016; 
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McFarlane, Becker & Field 2011), indicating that the excreted HeV may have higher 
chance to survive in cold temperatures (Scanlan et al. 2015). 
 
1.3 CLINICAL FEATURES 
As bats are the natural reservoir of the virus, there is a very little impact of HeV on 
flying foxes. Horses infected with HeV show the signs of pyrexia (raised body 
temperature), dyspnoea (shortness of breath) with increased heart rate. Neurological 
and respiratory signs are common among the infected horses (Marsh et al. 2011). 
Similar respiratory and neurological signs, which are seen in horses, are observed in 
human beings. Acute encephalitic syndrome is seen among humans infected with HeV 
(Mahalingam et al. 2012; O'sullivan et al. 1997). The first two fatal human cases were 
from acute respiratory illness and relapsing encephalitis respectively (O'sullivan et al. 
1997; Selvey et al. 1995). 
 
1.4 MODES OF TRANSMISSION 
HeV is observed to be transmitted to horses from flying foxes. The major routes of 
transmission are the body fluids or excretions of the bats, including urine, faeces, 
birthing fluids or saliva (Halpin et al. 2011). Urine of flying fox is the common route 
of excretion of virus (Edson et al. 2015; Field et al. 2011). Humans may become 
infected with HeV when they come in direct or close contact with the infected horses 
(Field 2016). Studies have shown that when mucous membranes and non-intact skin 
of humans are exposed to respiratory or nasal secretions, urine and blood of the 
infected horses, the virus may be transmitted (Murray et al. 1995; Playford et al. 2010; 
Wong et al. 2009). There’s no such records of transmission of HeV from flying foxes 
to human beings (Field 2016) and similarly, transmission between human beings has 
also been not reported (Hess et al. 2011). Pigs, cats, dogs, ferrets, guinea pigs and 
hamsters have been experimentally infected with HeV (Li, Embury-Hyatt & Weingartl 
2010; Westbury et al. 1996; Westbury et al. 1995; Williamson et al. 1998; Williamson 
et al. 2000) confirming that animals other than horses may also possess a potential 
threat of HeV transmission to humans. 
 
Figure 1.1. Transmission of HeV to humans 
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1.5 DIAGNOSTIC TOOLS FOR THE DETECTION OF HENDRA VIRUS 
Many diagnostic tools are available for the detection and diagnosis of HeV infection 
in horses ranging from molecular technique such as polymerase chain reaction to 
detect viral RNA to serological techniques such as ELISA and virus neutralization test 
to detect the presence of antibodies against the virus (Cowled et al. 2017a; Schmitt & 
Henderson 2005). Histological techniques and next generation sequencing methods 
are also very useful in diagnosing viral disease (Xiong et al. 2011). Snap test 
(O’Connor 2015), Loop Mediated Isothermal Amplification method (Mori & Notomi 
2009) and microRNA profiling method (Pritchard, Cheng & Tewari 2012) are some 
of the emerging techniques which aim to diagnose infectious diseases such as HeV 
disease in the field, or by shortening the time between infection and detection. 
 
1.5.1 VIRUS ISOLATION 
Virus isolation is one of the effective method in the diagnosis of Hendra virus infection 
which holds the importance during a new case or an outbreak. The isolated virus can 
be identified by the aid of electron microscopy, PCR of culture supernatants and 
neutralization with specific antisera (Daniels, Ksiazek & Eaton 2001). 
 
1.5.2 SEROLOGY (DETECTION OF ANTIBODIES) 
The infectious diseases in animals can be diagnosed by detecting the antibodies. The 
serological techniques depend upon the interaction between the antigens and 
antibodies. There are many serological techniques for the diagnosis of the disease; 
ELISA (Enzyme linked immunosorbent assay) and virus neutralization test being the 
most common ones. For the initial screening of the Hendra virus infection, ELISA is 
the most commonly used laboratory test. The two methods which are currently 
employed are indirect ELISA to detect IgG antibodies and capture ELISA to detect 
IgM antibodies to Hendra virus in horses. The live virus neutralization test is used as 
a reference standard to confirm the diagnosis of Hendra virus. The method uses the 
neutralizing antibody which is specific to the Hendra virus (Daniels, Ksiazek & Eaton 
2001; Mahalingam et al. 2012). Serological tests, although are not effective means of 
diagnosis of Hendra virus infection, can be used for the surveillance and 
epidemiological studies (Mahalingam et al. 2012). 
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1.5.3 POLYMERASE CHAIN REACTION 
Among many different diagnostic tools for the detection of virus, quantitative real-
time polymerase chain reaction (qPCR) is used most commonly. When the nucleic 
acids are amplified by this technique, pathogen-positive samples are detected by 
electrophoresis and sequencing. Real time PCR is the standard PCR technique used in 
veterinary laboratories to detect the infectious disease in animals. It decreases the 
possibility of cross contamination between the samples. There is no need of post PCR 
reaction in this technique. Real time PCR can be used even in the field due to the 
portable thermocyclers and lyophilized reagents. It will help in quick decision making 
during the outbreak of disease (Schmitt & Henderson, 2005). TaqMan based PCR 
assays are more sensitive as compared to conventional real time PCR as the results are 
obtained in a short period of time by this method (Smith et al. 2001). 
 
1.6 PREVENTION AND TREATMENT 
There are no commercially-approved therapies to treat animals or people infected with 
HeV. As a post exposure treatment, viral G glycoprotein targeted by human 
monoclonal antibody has been effective to some extent (Mire et al. 2014; Pallister et 
al. 2011). The spread of HeV infection can be controlled by vaccinating the horses 
against the virus (Middleton et al. 2014), wearing appropriate personal protective 
equipment while handling the infected horses (Hess et al. 2011) and during the post-
mortem examination of the horses as it carries a high risk for the transmission of the 
virus (Marsh et al. 2011). Most importantly, the contact of horses with the flying foxes 
and their excretion should be avoided so that horses won’t get infected with the virus 
and are unable to transmit the virus to humans. This can be done by preventing horses 
from grazing under trees where the prevalence of flying foxes are high (Hess et al. 
2011). Keeping sick horses in isolation can limit the exposure of human to the infected 
horses, thus, preventing the transmission of virus from horses to humans. 
 
2. DISEASE DETECTION BASED ON HOST RESPONSE 
HeV can be detected by the use of classical techniques such as virus isolation, 
serological detection and PCR. But these techniques can detect the infection when the 
infected horses show clinical signs and symptoms during which the disease is highly 
communicable. Therefore, if the disease is to be detected early, these diagnostic tools 
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are not useful. So, by studying the host immune response towards the infection, the 
disease can be detected as early as possible. This implies detecting the infection well 
before the signs and symptoms appear. The four fatal human cases that occurred due 
to HeV were the consequences from direct contact with the infected horses but no 
clinical signs were observed among all the horses at that particular time (Field et al. 
2010). The fact emphasises on the point that clinical features of HeV infection are non-
specific even with the late respiratory or neurological signs. Laboratory diagnosis of 
HeV, thus, becomes necessary and more so if the infection can be identified in pre-
clinical phase of infection. This would decrease the transmission of HeV infection 
among horses and humans, thus, helping in proper management of HeV outbreaks 
(Cowled et al. 2017). MicroRNA analysis has evolved as a potential technique to 
diagnose the disease as early as possible. 
 
Many different diseases, including the viral infections, can be diagnosed with the help 
of miRNA expression profiles (Chen et al. 2008). Recent study has shown that 
microRNA profiling technique can be considered as a useful tool to diagnose HeV 
infection in earlier stages of infection. The up-regulation of miR-146a in the blood 
sample of horses experimentally infected with the HeV proves the fact (Stewart et al. 
2013) though, the up-regulation of miR-146a has also been seen in other bacterial and 
viral infections (Boldin et al. 2011; Cameron et al. 2008; Hou et al. 2009). The up-
regulation and down regulation of many host miRNAs in horses infected with HeV 
make miRNA analysis as a potential biomarker for HeV infection (Cowled et al. 2017). 
 
3. MICRORNA 
3.1 PROPERTIES 
MicroRNAs (miRNA) are short, single stranded non-coding RNAs (about 22 
nucleotides in length) which regulate the expression of 30% of human genes at post 
transcriptional level by binding to specific messenger RNA (mRNA) targets 
promoting their degradation and inhibition of translation (Pritchard, Cheng & Tewari 
2012; Verma et al. 2016). The first miRNA was discovered in a nematode called 
Caenorhabditis elegans in early 90’s and was named lin-4 (Lee, Feinbaum & Ambros 
1993). Let-7 was the second miRNA discovered in the same nematode in 2000 A.D. 
associated with the timing of development (Reinhart et al. 2000). The activity of 
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hundreds of target genes can be regulated by the up regulation of a single miRNA 
(Bartel 2004; Hammond 2015). 
 
3.2 MICRORNA BIOGENESIS PATHWAY 
The primary miRNA (pri-miRNA) transcript is converted into a mature and active 
miRNA by undergoing a series of biogenesis steps (Figure 1). The stem-loop precursor 
RNA structure is the important feature of all miRNA genes as the strands of the stem 
act as source of mature miRNA (Hammond 2015). The miRNA host gene gets 
transcribed into primary miRNA with the help of RNA polymerase II (Lee et al. 2004). 
The flanking region of pri-miRNA gets cleaved within the nucleus by a microprocessor 
complex consisting of Drosha ribonuclease enzyme and an RNA binding protein 
DGCR8 (Han et al. 2004) to form an intermediate product called precursor miRNA 
(pre-miRNA) which is exported to cytoplasm by a protein named exportin 5 (Lund et 
al. 2004). The terminal loop of pre-miRNA is cleaved by endoribonuclease Dicer, 
which is associated with TRBP; an RNA binding protein to form miRNA duplex 
(Zhang et al. 2002). One strand of miRNA duplex binds to agronaute proteins (AGO) 
and loaded into RNA induced silencing complex (RISC) to form mature miRNA. The 
other strand called passenger strand gets degraded. The mature miRNA finds a 
complementary base pairs to that of target mRNA. Seed region (nucleotides 2 to 7 of 
miRNA) holds an important role in finding the target mRNA, thus, inhibiting protein 
synthesis either by inhibiting translation process or by degrading mRNA (Hammond 
2015). 
 
 
Figure 1.2: MicroRNA biogenesis pathway (Bhaskaran & Mohan 2014) 
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3.3 MICRORNAs AS PROMISING BIOMARKERS FOR DISEASE 
DIAGNOSIS 
In recent years, microRNAs-based assays have been developed to distinguish infected 
individuals. First, they are easily detected from the blood and urine samples, Secondly, 
once they are secreted in the blood and urine, they are stable (Gilad et al. 2008) which 
makes the disease diagnosis easy. Finally, they can easily be detected by using the 
most common sensitive molecular technique, the Polymerase Chain Reaction (PCR) 
(Cowled et al. 2017; Dong et al. 2013).  Due to their rich information content, 
accessibility in specimen such as plasma or serum and having greater sensitivity 
measurement, micro-RNAs are suitable for disease diagnosis and their study is useful 
as they can be potential biomarkers for different kinds of diseases (Pritchard, Cheng 
& Tewari 2012). A significant correlation has been established between the miRNA 
and the cause of disease making miRNA as a molecular biomarkers for detection of 
many different infectious diseases (Almeida, Reis & Calin 2011; Verma et al. 2016). 
It has been confirmed that the level of miRNA in blood or serum sample of the animals 
gets changed when they are infected with diseases i.e. they are differentially expressed 
in infected tissues (Verma et al. 2016; Wang, Chen & Sen 2016). The sensitivity, 
specificity, robustness and non-invasive nature of miRNA detection makes miRNA as 
an ideal choice for disease biomarker (Etheridge et al. 2011). Much of the progress in 
the study of miRNA as biomarker has been made in the diagnosis of various types of 
cancers (Ajit 2012; Correia et al. 2017; Cortez & Calin 2009; Pogribny 2018).    
 
Micro-RNA profiling method is one of the emerging tools in the diagnosis of various 
viral infections including the diagnosis of HeV. The technique involves the use of 
micro-RNA which can be used as a potential biomarker for disease detection 
(Bhaskaran & Mohan 2014; Dong et al. 2013; Pritchard, Cheng & Tewari 2012). The 
isolation of microRNA is quite similar to that of isolation of RNA with few 
modifications so that small RNA fraction can be retained. Quantitative reverse 
transcription PCR, microRNA microarray and RNA sequencing are the major RNA 
profiling techniques. Quantitative reverse transcription PCR can be used for absolute 
quantification. MicroRNA microarray technique has got fairly low cost and high-
throughput with respect to number of samples that can be processed per day. RNA 
sequencing has got high accuracy in distinguishing micro-RNAs which are quite 
similar in sequence (Pritchard et al., 2012). Micro-RNA profiling is used in early 
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diagnosis of HeV infection. Different reports have suggested that the level of micro-
RNA is elevated in infected horses as compared to healthy ones (Cowled et al. 2017; 
Stewart et al. 2013). 
 
A study was carried out for the transcriptome wide profiling of miRNAs in the whole 
blood of horses infected with HeV to know the host miRNA expression levels (Cowled 
et al. 2017). On the basis of the results obtained from the study done by Cowled et al., 
two miRNAs; miR-20a and miR-1842; were taken as the choice of miRNA for their 
analysis on the samples from horses infected with HeV. These two miRNAs gave the 
best possible results to be further analysed for HeV infection. The approach used in 
the study to detect HeV was to identify differential expression miRNAs on the basis 
of miRNA ratios. This serves as an internal normalization control (one molecule 
normalises the other molecule) while performing quantitative real time PCR. This 
approach is similar to the use of housekeeping genes. Evaluating the ratio of two 
different miRNAs help in determining if the average ratio for the infected horses and 
that of healthy horses is significantly different (Cowled et al. 2017). MicroRNA 20a 
belongs to miR-17 precursor family (Tanzer & Stadler 2004). It is located in 
chromosome number 13 in humans whereas in chromosome number 17 in horses 
(miRBase 2018a). miR-20a are over expressed in multiple cancer types such as human 
breast cancer, prostate cancer and cervical cancer (Cortez & Calin 2009; Zhao et al. 
2015). Over expression of miR-20a inhibits autophagy process (Guo et al. 2016). 
MicroRNA 1842 is located in chromosome number 13 of horses (miRBase 2018b). 
The functional relevance of miR-1842 is associated with the pathogenesis of acute 
lymphoblastic leukemia (ALL) (Zhang et al. 2009). 
 
Table 1: Sequence of miR-20a and miR-1842 
miRNA Nucleotide sequence Number of base pairs 
eca-miR-20a uaaagugcuuauagugcagguag 23 bp 
eca-miR-1842 uggcucugugaggucggcuca 21 bp 
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Figure 1.3: Location of miR-20a (red tick) and miR-1842 (green tick) in horse 
 
 
4. OBJECTIVES 
 
4.1 HYPOTHESIS 
The hypothesis of this project was that the ratio of miR-20a to that of miR-1842 can 
be potentially regarded as the tool to diagnose HeV infection in horses in the earlier 
stages of infection when no clinical signs and symptoms are shown by the infected 
animals. 
 
4.2 SPECIFIC AIMS 
1. Validating Taqman PCR primer-probes targeting miR-20a and miR-1842 
2. Examining the ratio in larger cohorts of animals (whole blood, serum) 
3. Examining whether miR-20a and miR-1842 are induced during the early stages of 
infection 
4. Assessing the ratio against other non-paramyxo virus (Kunjin virus, a West Nile 
virus) 
5. Assessing whether miR-20a and miR-1842 are induced by immune-ligands in vitro 
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CHAPTER II: MATERIALS AND METHODS 
 
2.1 MATERIALS 
Serum and blood of healthy and infected horses were the samples analyzed for the 
microRNA profiling. The project was carried out at Australian Animal Health 
Laboratory (AAHL), Geelong. The samples were collected from AAHL. The samples 
were provided to AAHL by New South Wales Department of Primary Industries, 
Biosecurity and Food Safety, New South Wales and Biosecurity Queensland, 
Department of Agriculture and Fisheries, Brisbane and the access was granted to use 
these samples for the research. All samples were collected from a disease outbreak at 
a single property in Hendra, Queensland in October 1994. Horses were infected with 
the same HeV strain (Hendra virus/horse/1994/Hendra) and tested positive for Hendra 
virus by a virus neutralization assay. Each sample had a titre greater than 32. Samples 
were stored at – 80 °C until processed for this study. 
 
2.1.1 MICRORNA ISOLATION 
miRNeasy mini kit (Qiagen, catalogue number 217004) was used for isolation of 
microRNA from blood samples; whereas for serum samples miRNeasy serum/plasma 
kit (Qiagen, catalogue number 217184) was used. The kit contents included 50 RNeasy 
mini spin column (each packaged with a 2 mL collection tube), 50 collection tubes 
(1.5 mL), 50 collection tubes (2 mL), Qiazol lysis reagent (50 mL), Buffer RWT (15 
mL, Buffer RPE (11 mL), RNase free water (10 mL). The miRNeasy mini kit was 
always at room temperature (25 °C). The other reagents/materials required were 
chloroform, 100% ethanol and 80% ethanol for blood samples and serum samples 
respectively, sterile RNase free pipette tips, pipettes of 20 µL, 200 µL and 1000 µL 
capacity, microcentrifuge tubes and disposable gloves. Microcentrifuge (with rotor for 
2 mL tubes) was required for centrifugation at 4 °C and at room temperature (25 °C). 
 
2.1.2 REVERSE TRANSCRIPTION OF ISOLATED miRNA 
TaqMan microRNA assays kit (Applied Biosystem) and TaqMan microRNA reverse 
transcription kit (Applied Biosystem) were used for the reverse transcription of 
isolated miRNA. TaqMan microRNA assays (catalog no. 4440886 and catalog no. 
4427975, Applied Biosysyem) included one tube containing small RNA specific RT 
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primer and one tube containing a mix of small RNA-specific forward PCR primer, 
specific reverse PCR primer and small RNA-specific TaqMan MGB probe. TaqMan 
microRNA reverse transcription kit (Applied Biosystem, part no. 4366596) included 
100 mM dNTPs, multiscribe reverse transcriptase (50U/µL), 10X reverse transcriptase 
buffer and RNase inhibitor (20U/µL) as kit components. The pure oligonucleotides 
(miR-20a and miR-1842 purchased from Thermofisher scientific) were required to 
optimise the qPCR assay by generating the standard curves for each of the microRNAs. 
The other reagents/materials required were nuclease free water, sterile RNase free 
pipette tips, pipettes of 20 µL, 200 µL and 1000 µL capacity, polypropylene tube, 
centrifuge, ice box and disposable gloves. Thermal cycler (T100, BioRad, catalog no. 
186-1096) was used to amplify microRNA segments. Nanodrop spectrophotometer 
(ND-1000, Nanodrop Technologies, Inc.) was the instrument used to determine the 
concentration of the isolated microRNA samples. 
 
2.1.3 QUANTITATIVE REAL TIME PCR (qPCR) AMPLIFICATION) 
TaqMan microRNA assays kit (Applied Biosystem, catalog no. 4440886 and catalog 
no. 4427975) was used for quantitative real time PCR amplification. It included one 
tube containing small RNA specific RT primer and one tube containing a mix of small 
RNA specific forward PCR primer, specific reverse PCR primer and small RNA-
specific TaqMan MGB probe. TaqMan Fast Universal PCR Master Mix (2X) (Applied 
Biosystem, no AmpErase UNG, catalogue no. 4352042, storage at 4 °C) was used for 
the amplification. The other materials required were 96 welled plate, parafilm cover, 
centrifuge with plate holder, disposable gloves, microcentrifuge, nuclease free water, 
vortex, polypropylene tubes, sterile RNase free pipette tips, pipettes of 20 µL, 200 µL 
and 1000 µL capacity and ice box. 
 
2.1.4 REAL TIME PCR DATA GENERATION 
To monitor the fluorescence as amplification of the cDNA occurs, specialised thermal 
cycler having fluorescence detection modules was used. In this case, it was step-one 
plus™ real time PCR system (Applied Biosystem, catalogue no. 4376600). 
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2.1.5 LYMPHOCYTE ISOLATION FROM HORSE BLOOD SAMPLES, CELL 
COUNT, CULTURE AND IMMUNE LIGAND STIMULATION 
For the isolation of lymphocytes from horse blood samples, lymphoprep™ (StemCell 
Technologies) was used (contains sodium diatrizoate (9.1% w/v), polysaccharides 
(5.7% w/v) and other ingredients). Dulbecco’s Phosphate-Buffered Saline with 2% 
Fetal Bovine Serum (PBS + 2% FBS) (StemCell Technologies, Catalog number 
07905) was used as a culture medium. For cell counting, Countess™ II Automated 
Cell Counter (Invitrogen™, catalogue No. C10227) was used. Horse lymphocytes 
were cultured in RPMI supplemented with 5% fetal bovine serum (FBS), 200 IU/mL 
Penicillin and 200 ng/mL Streptomycin. Poly(I:C) and lipopolysaccharides (LPS) 
(stock concentrations of 200 µg/mL) were used as immuno-stimulant (Sigma-Aldrich). 
Cells were incubated at 37 °C with 5% CO2.  
 
2.1.5.1 LYMPHOCYTE ISOLATION FROM HEALTHY HORSE BLOOD 
SAMPLES 
Five healthy horse blood samples (samples were provided by AAHL) were taken for 
the isolation of lymphocytes. For this, lymphoprep™ was thoroughly mixed by 
inverting the bottle several times. 10 mL of lymphoprep was added to 50 mL tube. 4 
mL of blood sample was diluted with an equal amount of Dulbecco’s Phosphate-
Buffered Saline with 2% Fetal Bovine Serum. Blood was layered on top of 
lymphoprep™, being careful not to mix blood with lymphoprep™. Tube was 
centrifuged at 600xg for 30 minutes at room temperature with brake off. Upper plasma 
layer was removed and discarded without disturbing the plasma:Lymphoprep™ 
interface. Lymphocyte layer was removed and retained at the plasma:Lymphoprep™ 
interface without disturbing erythrocyte/granulocyte pellet and was washed with the 
medium (StemCell Technologies 2017). Once isolated, the viable cells were then 
counted by Countess™ Automated Cell Counter. To get 5 x 106 cells per sample, 
required volume of isolated lymphocytes were calculated for each sample and 100 µl 
of the volume was allocated for each well (500,000 cells on average). 
 
2.1.5.2 STIMULATING THE LYMPHOCYTES WITH POLY(I:C) AND LPS 
Different concentrations of poly(I:C) and LPS (1 µg/mL, 10 µg/mL and 100 µg/mL) 
were prepared to stimulate the lymphocytes. 100 µL of the immune-ligands mixed 
with culture medium was required for each well (1 mL volume in total for 5 samples 
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with two different time periods- 4 hours and 24 hours). For this, 1.25 mL mixture of 
poly(I:C) and culture medium (same volume for LPS) was prepared (prepared in 
excess to compensate for volume loss during pipetting). The preparation was done by 
mixing 250 µL of poly i:c (stock concentration of 1 mg/mL) with 1 mL of the culture 
medium (RPMI 1640 supplemented with 5% FBS (foetal bovine serum), 200 IU/mL 
Penicillin and 200 ng/mL Streptomycin) to get a concentration of 200 µg/mL (same 
process repeated for LPS). 100 µL of 200 µg/mL concentration of immune-ligands 
was mixed with 100 µL of culture medium to get a concentration of 100 µg/mL. A 10 
fold dilution was carried out till the concentration of immune-ligands was made to 1 
µg/mL. One of the plate was incubated for 4 hours and the other plate was incubated 
for 24 hours at 37 °C, 5% CO2 (Hue et al. 2017). After incubation, the cells were 
harvested. 
 
2.1.5.3 HARVESTING THE LYMPHOCYTES 
The top 50 uL of the supernatant/media in each well was carefully taken off without 
disturbing the cells at the bottom of the wells. The cells in the plates were centrifuged 
at 600xg for 10 minutes. The rest of the supernatant from the wells was carefully 
removed without touching the bottom of the well and disturbing the pelleted cells (the 
plates tilted and was taken from the juncture of the bottom and the side). Plates were 
closed with the help of an autoclave tape and placed on ice to put into -80 °C storage 
with proper labelling. 
 
2.2 METHODS 
 
2.2.1 OPTIMIZATION OF qPCR ASSAY 
 
2.2.1.1 REVERSE TRANSCRIPTION 
Oligonucleotides (miR-20a and miR-1842) were first reverse transcribed to 
complementary DNA (cDNA) followed by a qPCR amplification of the synthesized 
cDNA (a two-step qRT-PCR). The reverse transcription was performed by preparing 
a RT reaction master mix. The TaqMan® microRNA reverse transcription kit 
components were allowed to thaw on ice and in a polypropylene tube, RT master mix 
was prepared by scaling the volumes as stated by the protocol (0.15 µL of 100mM 
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dNTPs, 1 µL of reverse transcriptase, 1.5 µL of 10X reverse transcriptase buffer, 0.19 
µL of RNAse inhibitor and 4.16 µL of nuclease free water for a single reaction) to the 
desired number of RT reactions (extra reactions prepared to compensate for losses that 
occur during pipetting). The master mix was gently mixed and pulse centrifuged to 
bring the solution to the bottom of the tube. The master mix was placed on ice until 
the RNA reaction was prepared. The miR-20a and miR-1842 oligonucleotides were 
diluted to the desired concentration i.e. 2 ng/µL (Input quantity: 10ng of total RNA; 5 
µL of RNA sample). RT master mix (7 µL) was added to each of the tube followed by 
5 µL each of diluted miR-20a and miR-1842 in the respective tubes. RT primer (3 µL) 
from each assay set (specific to each microRNA) was added to the respective tubes so 
that the total volume would be 15 µL. Samples were centrifuged to mix the solution 
properly. The tubes were incubated on ice for 5 minutes and then loaded on a thermal 
cycler. The parameter values used to program the thermal cycler were: 30 minutes on 
hold at 16 °C, 30 minutes on hold at 42 °C, 5 minutes on hold at 85 °C and finally on 
hold for infinity at 4 °C (Applied Biosystem 2011). cDNA samples were stored at -20 
°C. 
 
2.2.1.2 qPCR AMPLIFICATION OF cDNA SAMPLES 
The cDNA samples and TaqMan assays were gently vortexed followed by brief 
centrifugation. A 10-fold serial dilution of the cDNA samples (both miR-20a and miR-
1842) was carried out. To prepare the qPCR reaction mix, 10 µL of TaqMan universal 
fast PCR master mix, 1 µL of TaqMan small RNA assay and 7.67 µL of nuclease free 
water were pipetted for a single reaction into two micro-centrifuge tubes (one each for 
miR-20a and miR-1842). The volumes were adjusted according to the number of 
reactions required (done in duplicates and extra reactions prepared to compensate for 
losses that occur during pipetting). The tubes were capped and inverted several times 
to mix and centrifuged briefly. 18.67 µL of respective qPCR reaction mix (miR-20a 
and miR-1842) was transferred into each of the two corresponding wells on a 96-well 
plate. 1.33 µL of each of the serially diluted cDNA (miR-20a and miR-1842) was 
transferred to the respective wells so that the total volume would be 20 µL. The plate 
was sealed with a parafilm cover and was centrifuged at 12000xg for 1 minute 
(Applied Biosystem 2011). The plate was then loaded into the real time PCR system 
using the following parameters: a standard run mode with 20 µL sample volume and 
thermal cycling conditions as below: 
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Table 2: Thermal cycling conditions 
Step Enzyme activation PCR cycle (40) 
Hold Denature Anneal/Extend 
Temperature 95 °C 95 °C 60 °C 
Time 10 mins 15 seconds 60 seconds 
 
Afterwards, the molecular weight of each microRNA along with the copy number per 
reaction for each dilution was calculated with the help of DNA/RNA copy number 
calculator (Endmemo 2017). The standard curves for each microRNA was then 
generated by plotting the copy numbers against the Ct values generated from the real 
time PCR system for each diluted microRNA. Hence generated formula from the 
standard curves were used as a basis for calculating the copy numbers of each 
microRNA in the subsequent samples. The equation was in the form of y = mx + c; 
where ‘y’ represents Ct value of each sample and ‘x’ represents log quantity. Log 
quantity when raised to power of 10 gives the copy numbers (BioRad 2006). 
 
2.2.2 ANALYSIS OF miRNA-20a AND miR-1842 ON SERUM SAMPLES 
FROM HEALTHY HORSES, HORSES INFECTED WITH KUNJIN VIRUS, 
HORSES VACCINATED AGAINST HENDRA VIRUS AND SERUM AND 
BLOOD SAMPLES FROM HORSES INFECTED WITH HENDRA VIRUS 
 
2.2.2.1 ISOLATION OF MICRORNA FROM SERUM SAMPLES 
The isolation of microRNA from the horse serum samples was performed use the 
miRNeasy serum/plasma kit. Thirteen serum samples from horses infected with 
Hendra virus, five serum samples from horses infected with Kunjin virus, twenty 
serum samples from healthy horses and ten serum samples from horses vaccinated 
against Hendra virus were analysed for the microRNAs 20a and 1842. The frozen 
serum samples were thawed on ice. 100 µL of serum samples were mixed with 500 
µL of Qiazol lysis reagent by vortexing. The tubes were placed on the benchtop at 
room temperature (15–25 °C) for 5 minutes and 100 μL chloroform was added to the 
tubes and capped securely. Tubes were shaken vigorously for 15 seconds. The tubes 
were placed on the benchtop at room temperature for 2-3 minutes and centrifuged for 
15 minutes at 12000xg at 4 °C. After centrifugation, when the sample separates into 3 
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phases (upper, colourless, aqueous phase containing RNA; a white interphase 
containing DNA; and a lower, red, organic phase containing proteins), approximately 
300 µL of upper aqueous phase was transferred to a collection tube. 450 µL of 100% 
ethanol was added to the tubes and mixed thoroughly by pipetting up and down several 
times. 700 µL of the sample was pipetted out into an RNeasy mini spin column in a 2 
mL collection tube. The lid was gently closed and the tubes were centrifuged at 8000xg 
for 15 seconds at room temperature; the flow-through being discarded. 700 µL of 
buffer RWT was then added to the RNeasy mini spin column and centrifuged at 
8000xg for 15 seconds to wash the column; the flow through being discarded. 500 µL 
of buffer RPE was pipetted out to RNeasy mini spin column and centrifuged at 8000xg 
for 15 seconds; the flow through being discarded. 500 µL of 80% ethanol was added 
to the mini spin column and centrifuged at 8000xg for 2 minutes; the flow through 
being discarded along with the tube. The RNeasy mini spin column was placed into a 
new 2 mL collection tube; centrifuged at full speed for 5 minutes with the lid opened 
to dry the membrane. The collection tube was discarded along with the flow through. 
The RNeasy mini spin column was transferred to a new 1.5 mL collection tube. 14 µL 
of RNase free water was pipetted directly into RNeasy mini spin column membrane. 
The lid was closed gently and the tubes were centrifuged at full speed for 1 minute to 
elute the RNA (Qiagen 2012). The concentration of eluted miRNA samples were 
recorded with the help of a Nanodrop. All the samples were then diluted to a desired 
concentrations (10 ng of total RNA per 15 µL reaction) which were then used for the 
reverse transcription process. The original samples were stored at -80 °C. 
 
2.2.2.2 ISOLATION OF MICRORNA FROM BLOOD SAMPLES 
The isolation of microRNA from the horse blood samples was performed by the help 
of miRNeasy mini kit. Fifteen horse blood samples infected with Hendra virus were 
analysed for the microRNAs 20a and 1842. Among those 15 blood samples, each 5 
samples were from three different horses taken on each specific day after being 
infected with Hendra virus experimentally i.e. the first sample was taken on day zero, 
second sample on day 1, third sample on day 3, fourth sample on day 5 and fifth sample 
on day 7 (day 6 for one of the horses). For the isolation of microRNA, at first a quick 
spin was given to the blood samples and 700 μL of Qiazol Lysis Reagent was added. 
The tubes were placed on the benchtop at room temperature for 5 minutes and 140 μL 
chloroform was added to the tubes and capped securely. Tubes were shaken vigorously 
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for 15 seconds. The tubes were placed on the benchtop at room temperature for 2-3 
minutes and centrifuged for 15 minutes at 12000xg at 4 °C. After centrifugation, when 
the sample separates into 3 phases (upper, colourless, aqueous phase containing RNA; 
a white interphase containing DNA; and a lower, red, organic phase containing 
proteins), approximately 350 µL of upper aqueous phase was transferred to a collection 
tube. 525 µL of 100% ethanol was added to the tubes and mixed thoroughly by 
pipetting up and down several times. 700 µL of the sample was pipetted out into an 
RNeasy mini spin column in a 2 mL collection tube. The lid was gently closed and the 
tubes were centrifuged at 8000xg for 15 seconds at room temperature; the flow-
through being discarded. 700 µL of buffer RWT was then added to the RNeasy mini 
spin column and centrifuged at 8000xg for 15 seconds to wash the column; the flow 
through being discarded. 500 µL of buffer RPE was pipetted out to RNeasy mini spin 
column and centrifuged at 8000xg for 15 seconds; the flow through being discarded. 
Another 500 µL of buffer RPE was added to the mini spin column and centrifuged at 
8000xg for 2 minutes to dry the mini spin column membrane; the flow through being 
discarded along with the tube. The RNeasy mini spin column was placed into a new 2 
mL collection tube. The tubes were centrifuged at full speed in a microcentrifuge for 
1 minute; the flow through being discarded along with the tube. The RNeasy mini spin 
column was transferred to a new 1.5 mL collection tube. 35 µL of RNase free water 
was pipetted directly into RNeasy mini spin column membrane. The lid was closed 
gently and the tubes were centrifuged at 8000xg for 1 minute to elute the RNA (Qiagen 
2014). The concentration of eluted miRNA samples were recorded with the help of a 
Nanodrop. All the samples were then diluted to a desired concentrations (2 ng/µL) 
which were then used for the reverse transcription process. The original samples were 
stored at -80 °C. 
 
2.2.2.3 REVERSE TRANSCRIPTION OF ISOLATED MICRORNAs 
The reverse transcription was performed by preparing a RT reaction master mix. The 
TaqMan® microRNA reverse transcription kit components were allowed to thaw on 
ice and in a polypropylene tube, RT master mix was prepared by scaling the volumes 
as stated by the protocol (0.15 µL of 100mM dNTPs, 1 µL of reverse transcriptase, 1.5 
µL of 10X reverse transcriptase buffer, 0.19 µL of RNAse inhibitor and 4.16 µL of 
nuclease free water for a single reaction) to the desired number of RT reactions (extra 
reactions prepared to compensate for losses that occur during pipetting). The master 
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mix was gently mixed and pulse centrifuged to bring the solution to the bottom of the 
tube. The master mix was placed on ice until the RNA reaction was prepared. The 
samples were diluted to the desired concentration i.e. 2 ng/µL. 7 µL of RT master mix 
was added to each of the tube followed by 5 µL each of diluted RNA samples in the 
respective tubes. 3 µL of RT primer from each assay set (specific to each microRNA) 
was added to the respective tubes so that the total volume would be 15 µL. Samples 
were centrifuged to mix the solution properly. The tubes were incubated on ice for 5 
minutes and then loaded on a thermal cycler. The parameter values used to program 
the thermal cycler were: 30 minutes on hold at 16 °C, 30 minutes on hold at 42 °C, 5 
minutes on hold at 85 °C and finally on hold for infinity at 4 °C (Applied Biosystem 
2011). cDNA samples were stored at -20 °C. 
 
2.2.2.4 qPCR AMPLIFICATION OF cDNA SAMPLES 
The cDNA samples and TaqMan assays were gently vortexed followed by brief 
centrifugation. To prepare the qPCR reaction mix, 10 µL of TaqMan universal fast 
PCR master mix, 1 µL of TaqMan small RNA assay and 7.67 µL of nuclease free 
water were pipetted for a single reaction. The volumes were adjusted according to the 
number of reactions required (done in duplicates and extra reactions prepared to 
compensate for losses that occur during pipetting). The tubes were capped and inverted 
several times to mix and centrifuged briefly. 18.67 µL of respective qPCR reaction 
mix was transferred into each of the corresponding wells on a 96-well plate. 1.33 µL 
of each of cDNA was transferred to the respective wells so that the total volume would 
be 20 µL. The plate was sealed with a parafilm cover and was centrifuged at 12000xg 
for 1 minute (Applied Biosystem 2011). The plate was then loaded into the real time 
PCR system using the following parameters: a standard run mode with 20 µL sample 
volume and thermal cycling conditions as applied for serum samples. 
 
Ct values for each sample was recorded and the copy numbers of miR-20a and miR-
1842 for each sample were calculated by the help of the formula derived from the 
standard curves generated previously. The ratios between the two microRNAs were 
calculated and the data were plotted on the graph using Graph Pad Prism version 5. 
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2.2.3 MICRORNA ISOLATION, REVERSE TRANSCRIPTION AND qRT-
PCR ANALYSIS OF THE HARVESTED LYMPHOCYTES 
The isolation of microRNA from harvested lymphocytes was performed by the help 
of miRNeasy mini kit. In total 80 samples (16 for each of the 5 blood samples), 
stimulated with poly(I:C) and LPS for 4 hours and 24 hours, were analysed for the 
microRNAs 20a and 1842. For the isolation of microRNA, the plates containing the 
harvested cells were thawed on ice. 200 µL of Qiazol Lysis reagent was dispensed into 
each well and mixed thoroughly by pipetting up and down and transferred into a 
labelled eppendorf tube. The same process was repeated with another 200 µL volume. 
300 µL of Qiazol lysis reagent was finally added to the tube to make the volume 700 
µL. A quick spin was given to all the samples and the subsequent steps were performed 
as were performed for the blood samples as per the protocol (Qiagen 2014). The 
concentration of eluted miRNA samples were recorded with the help of a Nanodrop 
and diluted to the desired concentration (2 ng/µL). All the samples were stored at -80 
°C until reverse transcription was done. The same steps were performed for reverse 
transcription and qPCR amplification of the samples as was carried out before as per 
the protocol (Applied Biosystem 2011). 
 
2.2.4 STATISTICS 
The differences between groups were analyzed using Kruskal-Wallis test, a non-
parametric method. For analyzing the specific sample pairs, Dunn’s multiple 
comparison test was performed. 
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CHAPTER III: RESULTS 
 
3.1 OPTIMISATION OF qPCR 
The project was started by validating TaqMan primer-probe reagents used to detect 
miR-20a and miR-1842 by qRT-PCR. For this work purified synthetic microRNA 
oligonucleotides were used as PCR templates, both to validate the specificity of the 
reagents targeting miR-20a and miR-1842, but also to generate standard curves to 
determine the number of microRNA copies in subsequent analyses. The results 
obtained from the serial dilution of pure oligonucleotides (miR-20a and miR-1842) 
generated a standard curve (plotting log of starting quantity of template (ng) against 
the threshold cycle (Ct) value of each dilution obtained during the amplification, 
shown in Figures 3.1 and 3.2. Ct refers to threshold cycle; the cycle number at which 
detectable fluorescence signal is seen. The equation of linear regression line and the 
co-efficient of determination (R2 value; reflecting the linearity of the standard curve) 
determined the efficiency of the qPCR reactions (BioRad, 2006, Life Technologies, 
2012). The amplification curves and the standard curves for miR-20a and miR-1842 
show a linear relationship between microRNA template and Ct values, with R2 values 
between 0.96 and 0.99. 
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Figure 3.1. Standard curve generation for miR-20a. A. Amplification curves of the 
diluted templates. B. Standard curve with Ct value against the copy numbers 
 
 
 
 
 
 
 
 
 
A. 
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Figure 3.2. Standard curve generation for miR-1842. A. Amplification curves of the 
diluted templates. B. Standard curve with Ct value against the copy numbers 
 
 
3.2 MICRORNA RATIOS IN HENDRA INFECTED AND 
HEALTHY BLOOD SAMPLES ANALYZED IN PREVIOUS 
STUDY 
A recent study done by Cowled et al. to measure the ratio of miR-20a/miR-1842 in 
horse blood samples by next-generation sequencing showed clear differences between 
A. 
B. 
P a g e  | 35 
 
healthy horses and HeV infected horses (Figure 3.3C) (Cowled et al. 2017). This study 
was performed with a relatively small number of whole blood samples from six horses 
(three infected and remaining healthy controls). The level of miR-20a was up-
regulated among the HeV infected horses as compared to healthy controls (Figure 
3.3A); whereas levels of miR-1842 were lower (Figure 3.3B). When assessed as a ratio 
where expression levels of miR-20a are normalized according to miR-1842 expression 
levels, a clear and statistically-significant difference could be observed between the 
two groups (Figure 3.3C). The difference between groups was analyzed using a two-
tailed Student’s t test, with a p-value of <0.05 considered to be statistically significant. 
U
1
U
2
U
3
H
eV
1
H
eV
2
H
eV
3
0
200
400
600
800
1000
n
o
r
m
a
li
s
e
d
 c
o
u
n
t
(m
iR
-2
0
a
)
 
U
1
U
2
U
3
H
eV
1
H
eV
2
H
eV
3
0
200
400
600
800
n
o
r
m
a
li
s
e
d
 c
o
u
n
t
(m
iR
-1
8
4
2
)
 
 
U
1
U
2
U
3
H
eV
1
H
eV
2
H
eV
3
0
5
10
15
n
o
r
m
a
li
s
e
d
 r
a
ti
o
s
(m
iR
-2
0
a
/m
iR
-1
8
4
2
)
 
Figure 3.3. Ratio of miR-20a to miR-1842 in HeV infected and healthy horses (next 
generation sequencing results adapted from Cowled et al. (2017), A. Normalised 
count of miR-20a among 3 HeV infected and 3 healthy horses, B.  Normalised 
count of miR-1842 among 3 HeV infected and 3 healthy horses, C. Normalised 
ratio of miR-20a/miR-1842 among 3 HeV infected horses and 3 healthy horses. 
A. B. 
C. 
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3.3 MICRORNA RATIOS IN HENDRA INFECTED, HEALTHY 
AND VACCINATED SERUM SAMPLES 
Whilst next-generation sequencing results suggested a clear difference in miR-
20a/miR-1842 ratios in a small cohort of six horses, it was important to validate these 
results using qRT-PCR in a larger cohort of animals. It was also of interest to assess 
whether microRNA ratio levels in serum samples were consistent with those obtained 
in whole blood (Cowled et al. 2017). This point is particularly relevant from a disease 
diagnosis point of view, as serum samples are collected for HeV disease diagnosis 
more regularly than whole blood samples, due to their application in serology-based 
diagnostic assays. The ratio of miR-20a to miR-1842 was firstly analyzed in three 
categories of serum samples: horses infected with HeV, horses vaccinated against HeV 
and non-infected controls. (Figure 3.4). The purpose of this experiment was to assess 
whether the miR-20a/1842 ratio can distinguish infected from vaccinated animals.  
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Figure 3.4. MicroRNA ratio among healthy, HeV infected and vaccinated serum 
samples. 
 
A higher miRNA ratio was observed in HeV infected samples as compared to healthy 
ones and vaccinated samples when geometric means were calculated, though the result 
was not applicable to each horse serum sample. The results from this experiment 
suggested that changes. 
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3.4 MICRORNA RATIOS IN HENDRA INFECTED, HEALTHY 
SERUM SAMPLES AND SERUM SAMPLES INFECTED WITH 
KUNJIN VIRUS 
The ratio of miR-20a and miR-1842 were also analyzed in serum samples of horses 
infected with a kunjin virus (a non-paramyxo virus belonging to family Flaviviridae 
and genus Flavivirus) to assess whether this putative biomarker was specific to HeV 
disease, or was potentially a non-specific response to viral infection more broadly. 
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Figure 3.5. MicroRNA ratio among healthy, HeV infected and Kunjin infected serum 
samples. 
 
A higher miRNA ratio was observed in HeV infected samples as compared to healthy 
ones and samples infected with Kunjin virus when geometric means were calculated, 
though the result was not applicable to each horse serum sample (Figure 3.5). Results 
from these two experiments showed that (1) miR-20/1842 ratios that distinguish 
infected from healthy horses using whole blood as an analyte were also applicable to 
serum samples (2) the miR-20/1842 ratio showed differences between different 
infection types and also vaccination, suggesting that host microRNA responses may 
be able to specify infection type. 
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3.5 MICRORNA 20a AND MICRORNA 1842 ANALYSIS ON 
HENDRA POSITIVE BLOOD SAMPLES (REDLANDS TRIAL/ 
EXPERIMENTAL SAMPLES) 
Perhaps the biggest justification for developing a biomarker test for equine HeV 
disease is that current diagnostic tests cannot detect infection during the early stages 
of disease. This time in the disease process is critical from a human health perspective 
because it is during this time that horses may shed HeV through nasal secretions that 
are capable of infecting humans. It was therefore important to assess whether 
biomarker candidates such as the miR-20a/1842 ratio, respond during the early stages 
of disease where HeV is not detected by qPCR or serology. To this end microRNA 
ratios were assessed in whole blood collected at regular intervals during a controlled 
HeV infection trial conducted at the CSIRO Australian Animal Health Laboratory 
(AAHL) under bio-safety level (BSL)-4 conditions. Five blood samples (for five 
different time periods) from each of the three experimentally infected horses were 
tested for the miR-20a/1842 ratio. These ratios were compared to HeV genome levels 
as detected by HeV-specific PCR primers. The rectal temperature of the infected 
horses were also recorded during the trial, and are presented here to given an indication 
of the time post-exposure disease signs such as fever manifest. 
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Figure 3.6. Analysis of microRNA 20a and 1842 on the Hendra positive blood 
samples (Redlands Trial/Experimental samples) of Horse 1. A. MicroRNA ratio of 
the blood samples collected on day 0, 1, 3, 5 and 6 (on left y-axis) and HeV genome 
copies of the blood samples on the respective days (on right y-axis), B. Rectal 
temperature of the horse during the course of the infection 
 
Looking at the graph (Figure 3.6A), it can be said that miRNA ratio has been increased 
in earlier days of infection whereas the HeV genome were detected in later stages of 
the infection. The data indicated that HeV genome are not detected when the horse is 
in earlier stages of the infection but the ratio of miR-20a to the miR-1842 is higher 
during the earlier stages of the infection. Similarly, the temperature of the horse 
remained constant during the initial stage of the infection but it increased during the 
later stage of the infection (Figure 3.6B). 
 
While the miRNA ratio increased during the earlier stages of the infection in horse 1, 
no such similarity was seen in horse 2 (Figure 3.7A). The miRNA ratio was almost 
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equal in the earlier stages of the infection and decreased during the later stages of the 
infection. The HeV genome was detected only in day 7. Regarding the rectal 
temperature of the horse, the temperature was almost constant during the earlier stages 
of infection but increased during the later stages of the infection (Figure 3.7B). 
 
 
 
 
 
Figure 3.7. Analysis of microRNA 20a and 1842 on the Hendra positive blood 
samples (Redlands Trial/Experimental samples) of Horse 2. A. MicroRNA ratio of 
the blood samples collected on day 0, 1, 3, 5 and 7 (on left y-axis) and HeV genome 
copies of the blood samples on the respective days (on right y-axis), B. Rectal 
temperature of the horse during the course of the infection 
 
For horse 3, similar results were recorded as that for horse 1 i.e. the miRNA ratio has 
been increased in earlier days of infection whereas the HeV genome were detected in 
later stages of the infection (during days 5 and 7) (Figure 3.8A). Similarly, the 
temperature of the horse remained constant during the initial stage of the infection but 
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it increased during the later stage of the infection (sharp rise was seen on day 7) (Figure 
3.8B). 
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Figure 3.8. Analysis of microRNA 20a and 1842 on the Hendra positive blood 
samples (Redlands Trial/Experimental samples) of Horse 3. A. MicroRNA ratio of 
the blood samples collected on day 0, 1, 3, 5 and 7 (on left y-axis) and HeV genome 
copies of the blood samples on the respective days (on right y-axis), B. Rectal 
temperature of the horse during the course of the infection 
 
 
3.6 MICRORNA RATIOS IN THE LYMPHOCYTES (ISOLATED 
FROM HEALTHY HORSE BLOOD SAMPLES) STIMULATED 
WITH IMMUNE-LIGANDS 
Having demonstrated that the miR-20a/1842 ratio is up-regulated in serum and whole 
blood of horses infected with HeV, we next performed an experiment designed to 
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assess the mechanism of microRNA up-regulation. The hypothesis testing in the next 
experiment was that miR-20a/1842 ratio levels are up-regulated in blood and serum 
due to their up-regulated production in equine immune cells as part of an innate 
immune response. To test this, immune cells (lymphocytes) were isolated from fresh 
blood samples taken from five healthy horses and stimulated with two model ligands 
– intracellular poly(I:C) (polyinosinic:polycytidylic acid) – which acts as a mimic for 
intracellular viral RNA consistent with viral infection, and LPS (lipopolysaccharides) 
– a component of bacterial cell walls that mimics a bacterial infection. Both of these 
stimuli are known to induce robust innate immune responses, including the production 
of type I interferon cytokines (Reimer et al. 2008). The hypothesis tested in this 
experiment was that miR-20a/1842 up-regulation observed in horse blood and serum 
could also be induced by innate immune ligands.  The miRNA ratio was analyzed in 
lymphocytes stimulated with poly(I:C) and LPS of concentrations 1 µg/mL, 10 µg/mL 
and 100 µg/mL for 4 hours and 24 hours. The analysis of miRNA ratio was done in 
stimulated lymphocytes to know whether the miRNA gets upregulated or 
downregulated or remains the same as compared with the unstimulated lymphocytes. 
The miR-146a was taken as a positive control which was also induced by the immune-
ligands. This experiment demonstrated that the miR-20a/1842 ratio is responsive to 
LPS, and in particular, poly(I:C), a mimetic for RNA viral replication (Figures 3.9 and 
3.10). 
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Figure 3.9. MicroRNA ratios among the lymphocytes stimulated with poly(I:C) of 
different concentrations (1 µg/mL, 10 µg/mL and 100 µg/mL). A and B. MicroRNA 
ratio in the lymphocyte samples incubated for 4 hours and 24 hours respectively. C 
and D. MicroRNA 146a fold induction in lymphocyte samples incubated for 4 hours 
and 24 hours respectively. 
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Figure 3.10. MicroRNA ratios among the lymphocytes stimulated with LPS of 
different concentrations (1 µg/mL, 10 µg/mL and 100 µg/mL). A and B. MicroRNA 
ratio in the lymphocyte samples incubated for 4 hours and 24 hours respectively. C 
and D. MicroRNA 146a fold induction in lymphocyte samples incubated for 4 hours 
and 24 hours respectively. 
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CHAPTER IV: DISCUSSIONS AND CONCLUSION 
 
4.1 DISCUSSIONS 
Flying foxes are being responsible for the emergence of many different harmful viral 
diseases in the past 20 years with Hendra virus and Australian bat lyssavirus (in 
Australia) and Nipah virus (in Malaysia and Bangladesh) being viral diseases with 
high mortality rates in humans (Hsu et al. 2004; Yob et al. 2001). Improved diagnosis 
of these diseases in animal spill-over hosts, such as horses (HeV), pigs (NiV) or dogs 
(ABLV) will help in minimizing the zoonotic transmission of the diseases. The 
principal objective of this project was to assess whether Hendra virus infection in 
horses can be diagnosed in early stages of infection through the measurement of host 
responses.  
 
Host microRNA responses in horses infected with HeV were first identified in a 
previous study by our group (Cowled et al. 2017). The present study could be a starting 
point in answering a number of questions in near future stemming from our lab’s 
previous work. The changes in miR-20a/1842 ratio identified by next-generation 
sequencing can be validated by qPCR, providing confidence in the sequencing and 
bioinformatics protocols used for microRNA profiling. Current qPCR results do not 
validate results initially observed by next-generation sequencing. While up-regulation 
of the miR-20a/1842 ratio was observed in some instances, these trends were not 
statistically significant, and further work is required to more clearly define the 
potential of microRNAs as disease biomarkers. This further work may involve the 
analysis of additional microRNA candidates, the combinational assessment of other 
disease markers such as body temperature, or the study of additional host-derived 
biomarkers, such as proteins or metabolites. The changes in miR-20a/1842 ratio in 
whole blood samples can also be detected in serum samples, though not statistical 
significant. Prior to this study the expression of miR-20a and miR-1842 in horse serum 
had not been addressed. As serum samples are more commonly collected for disease 
diagnostics purposes, results from this study suggest that samples capture for serology 
diagnostic assays could be analyzed additionally for microRNA profiling. While the 
miR-20/1842 ratio was identified from horses not in the earliest stages of HeV disease 
(based on the HeV genome detected in whole blood samples), results from the present 
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study show that the miR-20a/1842 ratio is up-regulated in during the earliest stages of 
infection in two of three horses tested (Figure 3.6, Figure 3.8), suggest that the miR-
20a/1842 shows promise for early disease detection. However, no changes in the miR-
20a/1842 ratio were observed during infection of horse 2, suggesting that measuring 
the miR-20a/1842 ratio in insolation is not a suitable HeV disease biomarker. The 
present study also developed and validated Taqman qRT-PCR reagents targeting miR-
20a and miR-1842 for future use. Whilst equine miR-20a is homologous to miR-20a 
in other species, miR-1842 appears to be uniquely expressed in horses. It was therefore 
important to validate its expression in horse blood and serum samples. 
 
The present study also identifies a number of areas for future study.  Clearly, the 
measurement of miR-20a/1842 does not show significantly different values between 
all infected and healthy horses in this study. Further work is required to identify 
additional microRNAs, which when measured in combination with the miR-20a/1842, 
may provide greater statistical power to distinguish infected from healthy horses. This 
point is also illustrated in the up-regulation of the miR-20a/1842 ratio in only two of 
three horses in a controlled infection trial (Figure 3.6, Figure 3.8). It is important to 
note that measuring the relative expression levels of multiple host molecules is a 
common approach in the biomarker discovery space.  For example, the simultaneous 
measurement of three plasma proteins (CRP, TRAIL and IP-10) has recently been 
developed as a biomarker that distinguishes bacterial from viral respiratory infections 
(Oved et al. 2015). Measuring any one of these three molecules in isolation, whilst 
informative, cannot be used to detect or diagnose disease.  In this context, we would 
conclude that the present study identifies a microRNA ratio showing general 
differences between HeV-infected and non-infected horses, but further work is 
required to identify other microRNA ratios to improve diagnostic sensitivity and 
specificity. This study represents an important first step in this process. 
 
Another area for further research is around the issue of biomarker specificity.  If the 
biomarkers are specific for a particular disease, the diagnosis would be much easier. 
While the miR-20a/1842 ratio shows trends towards up-regulation in the serum of HeV 
infected horses compared to healthy controls (Figure 3.4), these changes are not 
statistically significant. Further work is clearly required to investigate other potential 
biomarkers, which when measured in concert with miR-20a/1842, may provide greater 
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distinction between infected and control groups. This increase in trend was not 
observed in the serum of horses infected with Kunjin (West Nile) virus (Figure 3.5), 
or in horses vaccinated against HeV (Figure 3.4).  This would suggest that the miR-
20a/1842 is specifically induced in response to HeV infection. LPS and poly(I:C) 
stimulation result in trends of up-regulation of the miR-20a/1842 ratio. Further work 
(which may include further biological replicates or measurement of additional 
microRNAs in combination with miR-20a and -1842) is required to determine whether 
these changes are statistically significant. Further studies, potentially with the 
assistance of next-generation sequencing, would enable a more comprehensive 
analysis of differential host microRNA responses in horses infected with different 
pathogens. Comparable studies performed by other groups do show a level of 
specificity of host microRNA responses both during in vitro and in vivo viral 
challenges (Foo et al. 2016; Stewart et al. 2013), however this specificity may require 
the measurement of many targets simultaneously. 
 
MicroRNAs have many important features to be considered as biomarkers because of 
their stability in body fluids such as blood, urine, saliva and they can easily be detected 
and measured by qRT-PCR (Etheridge et al. 2011). Due to this, miRNA can be used 
as a non-invasive biomarker (de Planell-Saguer & Rodicio 2011). The profile of 
miRNA can potentially be used as diagnostic, prognostic and predictive biomarkers. 
As a diagnostic biomarker, it can be used to detect the disease. MiRNA has a huge 
potential as prognostic biomarker which helps in predicting disease outcome whereas 
as predictive biomarkers they can be useful to know the effectiveness of the treatment 
(de Planell-Saguer & Rodicio 2011; Nalejska, Mączyńska & Lewandowska 2014). 
Many studies show a connection between infectious disease and alterations in 
expression of miRNA (Murata et al. 2010; Ng et al. 2009; Wang et al. 2010), while 
the study of miRNA as biomarkers have been extensively done in the field of 
oncology. For example, the level of miR-141 in serum can differentiate prostate cancer 
from healthy persons (Mitchell et al. 2008), oral cancer has been associated with down 
regulation of miR-125a and miR-200a (Park et al. 2009) and detection of bladder 
cancer can be done by analyzing the ratio of miR-126 and miR-182 in urine samples 
(Hanke et al. 2010). With regards to virus infection, several studies have been 
conducted on circulating miRNAs. Some of these studies are related to HIV in which 
miR-150 is considered as a potential biomarker for HIV/AIDS (Munshi et al. 2014) 
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and hepatitis C virus in which miR-122 was found to be up-regulated (Akamatsu et al. 
2015). The miRNA profiles have been studied in other viral infections as well 
including rabies virus (Han et al. 2011) and ebola virus (Duy et al. 2016). 
 
Future work may also address the sensing technologies required to detect microRNAs 
for disease diagnostic purposes, especially in the context of field-detection. The 
development of inexpensive detection method to accurately measure miRNA levels 
remain the other challenges to use miRNA as diagnostic biomarkers (de Planell-Saguer 
& Rodicio 2011; Wang, Chen & Sen 2016). Other questions remain around the 
regulation of biomarker test use.  Given that HeV is a notifiable disease, it is important 
to consider who would use these tests in the future, and how their use would be 
regulated. One possible scenario is that biomarker tests would be considered as 
companion diagnostics to enable faster investigation and management of disease 
outbreaks, while all test results result in a comprehensive laboratory investigation. As 
HeV disease can be fatal in humans, it is important that future biomarker tests are 
performed by experienced and trained staff.  Growing interest in field-based testing 
for important animal diseases can be illustrated by the development and deployment 
of portable LAMP-based assays (Parida et al. 2008) against major pathogens such as 
HeV and foot-and-mouth disease virus. 
 
Each research has its own limitations and the present research is no exceptional. 
MicroRNA 20a and 1842 were chosen for the study to see whether the ratio of these 
microRNAs can provide an insight in detecting Hendra virus infection in horses as 
early as possible. The results showed some promising scenario though couldn’t 
confirm whether the ratio of these microRNAs in infected horses can address the issue. 
Though the results couldn’t reach the statistical significance, there seems a trend that 
the ratio of these microRNAs can possibly be regarded as a factor to differentiate the 
HeV infected horses from the healthy controls. More studies are needed to confirm 
this. Further biological replicates or measurements of additional microRNAs in 
combination with microRNAs 20a and -1842 is required so as to get the significant 
result which can help in distinguishing between infected and control groups. The study 
of additional host-derived bio-markers such as proteins or metabolites can help in 
defining the potential role of microRNAs as disease bio-markers. The serum samples 
tested lack the additional information such as body temperature and duration for which 
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the animals have been infected. The clinical signs and symptoms of the infected groups 
are not available, which if were known, could have provided a more clear insight 
regarding the detection of the disease. 
 
 
4.2 CONCLUSION 
The detection and diagnosis of infectious diseases through the study of host immune 
responses to infection is an emerging concept, made possible by the increasingly 
availability of platform technologies such as next-generation sequencing that allow us 
to comprehensively study and harness animal immune responses to infection. The 
identification of informative biomarkers not only help us to understand the physio-
pathological processes of the diseases but also help in diagnostic assay development. 
Whilst not applicable for all animal diseases, HeV disease diagnosis in the future has 
the potential to be improved by host biomarkers, due to the gap in time between 
infection and positive test results using existing assays.  In summary, the circulating 
expression profile of a particular microRNA ratio, miR-20a/1842, shows some 
differences between healthy horses and those infected with HeV.  This response was 
not observed in horses vaccinated against HeV, or infected with West Nile virus, 
suggesting some level of specificity. Though further work needs to be done to establish 
miRNA as diagnostic biomarker, results from this study show that the profiling of host 
miRNA in a viral infection shows promise as a new approach in diagnosing infectious 
diseases in the future. 
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